ArticleArchives of endocrinology and metabolism2026
The Brazilian Transition in Differentiated Thyroid Carcinoma Management: A 25-Year Nationwide Analysis of Declining High-Activity Radioiodine Use (2000-2024).
Article in Archives of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze temporal trends in radioiodine (RAI) prescription patterns for differentiated thyroid carcinoma (DTC) in Brazil from 2000 to 2024, assessing adherence to evolving clinical guidelines and identifying opportunities for practice optimization. MATERIALS AND
methodsThis retrospective study utilized data from the Brazilian Unified Health System (Datasus) to evaluate RAI prescriptions, categorized by activity: low (30 and 50 mCi), high (100 and 150 mCi), and very high (200 and 250 mCi). Population-adjusted rates, procedure-adjusted ratios (RAI/oncologic thyroidectomies and RAI/new cases), and activity-level trends were analyzed.
resultsThree distinct phases emerged: () 2000-2007, marked by increasing very high-activity RAI use (≥ 200 mCi); () 2008-2015, peak utilization with initial diversification (introduction of 30/50 mCi in 2014); and () 2016-2024, significant de-escalation, with high/very high-activity prescriptions declining by 34.2% and low-activity use increasing by 163%. By 2024, RAI distribution comprised 15.3% very high-, 67.1% high-, and 17.6% low-activity prescriptions. The RAI/new cases ratio fell sharply from 0.63 (2010) to 0.25 (2024), and RAI/oncologic thyroidectomies dropped from 1.22 (2013) to 0.70 (2024), reflecting more selective prescription.
conclusionBrazilian medical practice has increasingly aligned with international DTC guidelines, showing a decline in RAI use and a shift toward low-to-high RAI activities. This suggests broader adoption of risk-adapted strategies. Notwithstanding, high-dose RAI still predominates, pointing that dissemination of standardized treatment protocols could further enhance DTC care within the Brazilian health system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.